title: Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract.
abstract: BACKGROUND
  The efficacy of triple-drug combination regimens such as docetaxel, cisplatin and 5-fluorouracil (DCF), and epirubicin, oxaliplatin and capecitabine (EOX), is superior to standard cisplatin/5-fluorouracil in patients with upper gastrointestinal adenocarcinoma. In this analysis, we compare DCF and EOX regarding toxicity and efficacy.
  
  
  METHODS
  Patients received either intravenous docetaxel at 75 mg/m(2), cisplatin at 75 mg/m(2), both given on day 1, and 5-fluorouracil at 750 mg/m(2), on days 1 to 5, or epirubicin at 50 mg/m(2) i.v. on day 1, oxaliplatin at 130 mg/m(2) i.v. on day 1 and capecitabine at a twice-daily dose of 1000 mg/m(2) p.o. for two weeks; both regimens were repeated every three weeks.
  
  
  RESULTS
  Response rates for DCF and EOX were 28% and 10%, time-to-progression was 26 and 20 weeks, and overall survival were 54 and 52 weeks, respectively.
  
  
  CONCLUSIONS
  We conclude that further investigations within comparative prospective clinical trials of these regimens are warranted.
authors.affiliation: Department of Medicine I, Division of Oncology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
authors.forename: Aysegül
authors.initials: A
authors.lastname: Ilhan-Mutlu
authors.forename: Matthias
authors.initials: M
authors.lastname: Preusser
authors.forename: Sebastian F
authors.initials: SF
authors.lastname: Schoppmann
authors.forename: Reza
authors.initials: R
authors.lastname: Asari
authors.forename: Ahmed
authors.initials: A
authors.lastname: Ba-Ssalamah
authors.forename: Katrin
authors.initials: K
authors.lastname: Schwameis
authors.forename: Ursula
authors.initials: U
authors.lastname: Pluschnig
authors.forename: Peter
authors.initials: P
authors.lastname: Birner
authors.forename: Andreas
authors.initials: A
authors.lastname: Püspök
authors.forename: Johannes
authors.initials: J
authors.lastname: Zacherl
authors.forename: Michael
authors.initials: M
authors.lastname: Hejna
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000069287:Capecitabine; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077143:Docetaxel; D015251:Epirubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use; D000077150:Oxaliplatin; D010166:Palliative Care; D012189:Retrospective Studies; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D041742:Upper Gastrointestinal Tract / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D043823:Taxoids; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000077143:Docetaxel; D015251:Epirubicin; D000069287:Capecitabine; D002945:Cisplatin; D005472:Fluorouracil
keywords: 5-fluorouracil; Epirubicin; G-CSF; adenocarcinoma; capecitabine; cisplatin; docetaxel; gastroesophageal cancer; oxaliplatin